Showing results (1-10 of 180) with videos related to
Sort By:
Pageof 18
The Lancet. Oncology|June 3, 2004
Non-Hodgkin lymphoma: an updateBryan T Hennessy, Emer O Hanrahan, Peter A DalyExpert Opinion on Pharmacotherapy|August 10, 2005
Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trialsEmer O Hanrahan, Bryan T Hennessy, Vicente ValeroClinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancerEmer O Hanrahan, John V HeymachJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literatureEmer O Hanrahan, Vicente Valero, Ana M Gonzalez-Angulo, et al.Clinical Medicine Insights. Oncology|December 3, 2015
Obesity Correlation With Metastases Development and Response to First-Line Metastatic Chemotherapy in Breast CancerMohammed A Osman, Bryan T HennessyDrugs|June 15, 2011
Molecular targeted therapy in ovarian cancer: what is on the horizon?Roshni Kalachand, Bryan T Hennessy, Maurie MarkmanLancet (London, England)|October 2, 2009
Ovarian cancerBryan T Hennessy, Robert L Coleman, Maurie MarkmanMolecular Biology Reports|June 28, 2024
Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell modelsBritta Stordal, Angela M Farrelly, Bryan T HennessyFrontiers in Endocrinology|April 19, 2021
New Roles for Vitamin D Superagonists: From COVID to CancerDavid J Easty, Christine J Farr, Bryan T HennessyThe Journal of Clinical Investigation|April 15, 2011
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategySeth A Wander, Bryan T Hennessy, Joyce M SlingerlandPageof 18